Cara Therapeutics | CARA - Gross Profit On Sales


Cara Therapeutics reported $2.57M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Chugai Pharma JPY 237.37B 21.38B Jun/2026
Cipla INR 44.1B 5B Jun/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 352K 63.44M Mar/2026
CSL USD 4.46B 2.71B Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
J&J USD 18.55B 6M Sep/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pacira USD 133.91M 7.27M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
RedHill Biopharma USD 584K 0 Jun/2024
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024